Princess Margaret Hospital, Toronto, ON, Canada
Sue Richter , Ashraf AlMatar , Nafisha Lalani , Jackie Bender , David Wiljer , Laura Legere , Christine Massey , Nour Alkazaz , Majula Maganti , Pamela Catton , Srikala S. Sridhar , Michael A. Jewett
Background: Genitourinary (GU) cancer survivors comprise nearly 25% of cancer survivors and >50% of all male survivors. To further improve care of this patient population, we need to better understand physician specialist perceptions of survivorship care. Methods: All medical oncologists, urologists and radiation oncologists treating GU cancers in Canada were surveyed with a web−based questionnaire. A total of 27 multiple choice and Likert scale questions were developed in 5 domains: i) demographics, ii) current post cancer treatment care practices, iii) perceived barriers, iv) accessibility to survivorship resources and v) perceptions of advocacy groups. Participants were identified through their respective professional associations. Results: There were 306 responses and 260 were eligible for analysis; 45 medical oncologists, 125 urologists and 90 radiation oncologists. A total of 56% of physicians discharged GU cancer survivor follow-up care to a primary care practitioner (PCP) at some point after treatment. Compared to urologists and radiation oncologists, medical oncologists were least likely to share care with a PCP (4%). Only 47% of all physicians consistently provided a written follow up plan to the PCP and only 25% of these provided lifeclass recommendations. Lack of time and resources were the most commonly reported barriers. About half of physicians reported access to cancer rehabilitation programs as difficult and British Columbia was the most frequently cited region without access. Medical oncologists compared to other subspecialties accessed genetic counseling more easily while access to pain management programs was cited as the most difficult. In general, physicians in community hospitals had the most difficulties. Utilization of advocacy groups was limited, e.g. 23% for prostate cancer. The most underutilized advocacy group was for testis cancer (4%). Conclusions: To our knowledge this is the first study to address the challenges of GU cancer survivorship care in Canada. The barriers to care and underutilization of advocacy groups quoted in this study may be used to stimulate nationwide initiatives to further long-term strategies in GU survivorship management planning.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Ilana Yurkiewicz
2022 ASCO Quality Care Symposium
First Author: Ambrish Pandit
2023 ASCO Quality Care Symposium
First Author: Caroline Schenkel
2023 ASCO Quality Care Symposium
First Author: Alexandra G. Peluso